Artiva Biotherapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Artiva Biotherapeutics, Inc. (ARTV) reported Capital Expenditures Incurred but Not yet Paid of $14.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$284.00K.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $298.00K, a 66.21% decline year-over-year.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was -$134.00K, a 385.11% decline year-over-year.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $143.00K.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $292.00K, a 412.28% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $57.00K, a 216.67% increase from fiscal 2023.
- Artiva Biotherapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $18.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.00K 10-Q · filed 2026-08-06 | -$120.00K derived: sum of 3 quarters · filed 2026-08-06 | $23.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $298.00K 10-Q · filed 2026-05-08 | $164.00K derived: sum of 2 quarters · filed 2026-05-08 | $307.00K derived: sum of 3 quarters · filed 2026-05-08 | -$292.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.00K derived: sum of 2 quarters · filed 2026-03-10 | -$590.00K derived: sum of 3 quarters · filed 2026-08-06 | $292.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$456.00K derived: sum of 2 quarters · filed 2026-08-06 | $426.00K 10-Q · filed 2025-11-12 | $473.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$599.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $283.00K 10-Q · filed 2026-08-06 | $330.00K derived: sum of 3 quarters · filed 2026-08-06 | $307.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $882.00K 10-Q · filed 2026-05-08 | $929.00K derived: sum of 2 quarters · filed 2026-05-08 | $906.00K derived: sum of 3 quarters · filed 2026-05-08 | $926.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $24.00K derived: sum of 2 quarters · filed 2026-03-10 | $44.00K derived: sum of 3 quarters · filed 2026-03-10 | $57.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$3.00K derived: sum of 2 quarters · filed 2025-11-12 | $10.00K 10-Q · filed 2025-11-12 | -$589.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $33.00K 10-Q · filed 2025-08-06 | -$566.00K derived: sum of 3 quarters · filed 2025-08-06 | -$15.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $13.00K 10-Q · filed 2025-05-08 | -$586.00K derived: sum of 2 quarters · filed 2025-05-08 | -$35.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$48.00K derived: sum of 2 quarters · filed 2025-03-24 | $18.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $617.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $66.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |